Endocrinology
Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.
Recent Discussions
Do you start finerenone right away or wait for better glycemic control in a patient with CKD, type 1 diabetes, an HbA1c of 10% or higher, and persistent albuminuria on a maximally tolerated ACE inhibitor or ARB?
Good question – this has been looked at (Beernink et al, PMID 42258447), and benefits and safety are independent of A1c. Accordingly, it is reasonable to start finerenone at essentially any level of A1c, unless there is concern that the patient has an osmotic-induced state of volume depletion.
What could cause a sudden rise in LDL cholesterol in young adults who have not changed their lifestyle or started any new medications?
Depending on the degree of the rise in LDL-C noted, there are a number of reasons. Despite the person reporting that they have "not changed their lifestyle," one must consider either reduced activity or a diet with more saturated fat, due to being less diet-conscious, or due to a low-carbohydrate or...
How do you proceed when the calcium-to-creatinine clearance ratio is between 0.01 and 0.02 in a patient with suspected primary hyperparathyroidism?
If has had normal calcium levels in the past, it is not FHH which is genetic, but likely to be due to negative calcium balance, either deficient intake or absorption.
What glucose lowering therapy do you recommend using when patients are discharged from hospital after being admitted with euglycemic DKA secondary to SGLT2i use?
Stop the SGLT-2. Continue other previous therapy and adjust dosage as needed.
Do you add a potassium binder to continue finerenone when hyperkalemia develops in a patient with CKD and type 1 diabetes?
In general, I do not recommend adding a new agent to counteract the side effects of another agent. Adding the second medication only makes sense in clinically dire situations with no alternative to treatment, as is seen in the oncology world. I do not think there is sufficient evidence of long-term ...
Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?
The short answer is no, unless the patient has an indication like osteoporosis. Bisphosphonates have been evaluated in smoldering multiple myeloma in studies performed over 10 years ago. Treatment with pamidronate (D’Arena et al., 2011) or zoledronic acid (Musto et al., 2008) did not affect the time...
How do you counsel patients on the risk of non-arteritic anterior ischemic optic neuropathy (NAION) with use of GLP 1 R agonist therapy?
I counsel patients on the risk of NAION with GLP-1RA therapy as follows: NAION is a rare condition that can cause blindness, usually just in one eye. It occurs in less than 1 in 10,000 people. It is unclear whether the GLP-1 drugs actually cause NAION, but they might. If they do, the best evidence i...
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
The approach that has been recommended may be reasonable. It is important to recognize that a bone density score consistent with osteoporosis does not necessarily mean that the patient has osteoporosis i.e. loss of mineral and matrix. Osteomalacia, a mineralization defect of the collagen elastin mat...
Do you consider adding a GLP-1 receptor agonist to insulin therapy in a patient with newly diagnosed LADA who has not yet progressed to insulin dependence?
Auto-immune diabetes is known to have identifiable stages of beta-cell dysfunction and demise and being able to intervene with a treatment to preserve or improve beta-cell function is one of the major areas of diabetes research. Latent auto-immune diabetes presenting in adults (LADA) at a time when ...
How do you approach checking an aldosterone to renin ratio in an outpatient with hypertension and hypokalemia that is difficult to correct with oral potassium replacement?
It is well known that hypokalemia can affect the aldosterone-renin ratio (ARR). Since hypokalemia directly inhibits aldosterone production, this can lead to false negative results when using ARR to screen for primary aldosteronism. If it is difficult to correct hypokalemia with oral potassium repla...